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Abstract
Purpose: We recently developed a chelating platform based on the macrocycle 1,4,7-
triazacyclononane with up to three five-membered azaheterocyclic arms for the preparation of
68Ga- and 64Cu-based radiopharmaceuticals. Based on this platform, the chelator scaffold NOTI-
TVA with three additional carboxylic acid groups for bioconjugation was synthesized and
characterized. The primary aims of this proof-of-concept study were (1) to evaluate if trimeric
radiotracers on the basis of the NOTI-TVA 6 scaffold can be developed, (2) to determine if the
additional substituents for bioconjugation at the non-coordinating NH atoms of the imidazole
residues of the building block NOTI influence the metal binding properties, and (3) what
influence multiple targeting vectors have on the biological performance of the radiotracer. The
cyclic RGDfK peptide that specifically binds to the αvß3 integrin receptor was selected as the
biological model system.
Procedures: Two different synthetic routes for the preparation of NOTI-TVA 6 were explored.
Three c(RGDfK) peptide residues were conjugated to the NOTI-TVA 6 building block by
standard peptide chemistry providing the trimeric bioconjugate NOTI-TVA-c(RGDfK)3 9.
Labeling of 9 with [64Cu]CuCl2 was performed manually at pH 8.2 at ambient temperature.
Binding affinities of Cu-8, the Cu2+ complex of the previously described monomer NODIA-Me-
c(RGDfK) 8, and the trimer Cu-9 to integrin αvß3 were determined in competitive cell binding
experiments in the U-87MG cell line. The pharmacokinetics of both 64Cu-labeled conjugates
[64Cu]Cu-8 and [64Cu]Cu-9 were determined by small-animal PET imaging and ex vivo
biodistribution studies in mice bearing U-87MG xenografts.
Results: Depending on the synthetic route, NOTI-TVA 6 was obtained with an overall yield up to
58 %. The bioconjugate 9 was prepared in 41 % yield. Both conjugates [64Cu]Cu-8 and
[64Cu]Cu-9 were radiolabeled quantitatively at ambient temperature in high molar activities of Am
~ 20 MBq nmol−1 in less than 5 min. Competitive inhibitory constants IC50 of c(RDGfK) 7, Cu-8,
and Cu-9 were determined to be 159.5 ± 1.3 nM, 256.1 ± 2.1 nM, and 99.5 ± 1.1 nM,
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respectively. In small-animal experiments, both radiotracers specifically delineated αvß3 integrin-
positive U-87MG tumors with low uptake in non-target organs and rapid blood clearance. The
trimer [64Cu]Cu-9 showed a ~ 2.5-fold higher tumor uptake compared with the monomer
[64Cu]Cu-8.
Conclusions: Functionalization of NOTI at the non-coordinating NH atoms of the imidazole
residues for bioconjugation was straightforward and allowed the preparation of a homotrimeric
RGD conjugate. After optimization of the synthesis, required building blocks to make NOTI-TVA
6 are now available on multi-gram scale. Modifications at the imidazole groups had no
measurable impact on metal binding properties in vitro and in vivo suggesting that the NOTI
scaffold is a promising candidate for the development of 64Cu-labeled multimeric/multifunctional
radiotracers.
Key words: Copper-64, Integrins, αvß3, PET imaging, Bifunctional chelator, Multimerization,
Trimer, NODIA-Me, NOTI
Background
Bifunctional chelators (BFCs) are an integral part of metal-
based, target-specific radiopharmaceuticals for cancer diag-
nosis and therapy. A BFC acts in two roles: (1) to stably
complex the radiometal to prevent premature loss of the
radiolabel in vivo and, thus, radioactivity accumulation in
non-target tissues; and (2) to provide a second functionality
for covalent linkage to a tumor-specific targeting vector. An
ideal BFC should also be characterized by rapid complex
kinetics and provide the radiotracer in high radiochemical
yield (RCY) and high molar activity. In general, a metal-
based target-specific radiotracer is comprised of one target-
ing vector coupled to one BFC. For the majority of
commonly used macrocyclic BFCs such as DOTA (=
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)
and NOTA (= 1,4,7-triazacyclononane-1,4,7-triacetic acid),
one of the acetic acid arms is generally used for bioconju-
gation [1–4]. However, since the carboxylate-O donors of
the acetic acid residues are also required for metal
complexation, not more than one targeting moiety is usually
attached to these BFCs via peptide bond formation to avoid
the risk of compromising the metal binding, thus limiting
their application to the design of monovalent radiotracers.
Furthermore, other conjugation strategies such as click
chemistry require additional modifications of these BFCs
by either (1) coupling corresponding functionalities to the
acetic acid residues through amide formation or (2)
substitution of an acetic acid residue, thereby increasing
the synthetic efforts [5–8]. Moreover, approaches for the
design of multivalent/multimeric radiotracers usually con-
nect multiple targeting vectors/biomolecules via additional
aliphatic chains using, e.g., poly-glycine, poly-lysine, poly-
proline, or poly-ethyleneglycol linkers to which the metal
chelator or 18F-radiolabeled prosthetic group is conjugated
terminally [9–16]. This approach has commonly been used
for an array of chelators including DOTA and NOTA, as
well as for other radiolabels due to their limited number of
functionalities for bioconjugation often only allowing the
conjugation of a single biomolecule [9–16]. In addition to
the additional synthetic steps, these aliphatic modifications/
linkers however may increase the overall lipophilicity of the
entire molecule, potentially resulting in unfavorable phar-
macokinetics and high uptake in non-target organs.
An alternative design of multivalent/multifunctional
radiopharmaceuticals is the use of metal chelators that (1)
intrinsically provide several functionalities for bioconjuga-
tion and (2) that can serve as the central unit of the
radiotracer with no need for additional aliphatic linkages of
the targeting vectors. In this respect, we recently introduced
a chelating platform based on the macrocycle 1,4,7-triaza-
cyclononane (TACN) with additional five-membered azahe-
terocyclic arms (Scheme 1) [17]. The chelators NOTI 1
(1,4,7-tris((1H-imidazol-2-yl)methyl)-1,4,7-triazonane),
NOTI-Me 2 (1,4,7-tris((1-methyl-1H-imidazol-2-yl)methyl)-
1,4,7-triazonane), and NOTThia (1,4,7-tris(thiazol-2-
ylmethyl)-1,4,7-triazonane) were originally designed for the
complexation of the positron-emitting radionuclide copper-
64 which has favorable decay properties for PET (positron
emission tomography). The half-life of 64Cu (t1/2 = 12.7 h)
allows delayed imaging and investigation of biological
Scheme 1 Chelating platform based on the TACN macro-
cycle with additional five-membered azaheterocyclic arms.
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processes at later time points for biomolecules/targeting
vectors with intermediate pharmacokinetics such as peptides
as well as nano- and minibodies. Before the availability of
the positron-emitter 89Zr (t1/2 = 3.3 d),
64Cu has also been
used for PET imaging with long-circulating biomolecules
such as immunoglobulins or related fragments [18]. More-
over, the positron energy of 64Cu (Eβ+,max = 653 keV; 18 %)
is comparable with that of the PET gold standard 18F
(Eβ+,max = 633 keV) and its dual decay characteristics with
its positron and beta (Eβ-,max = 578 keV; 37 %) emissions
allow diagnostic PET imaging and, in principle, radionuclide
therapy with the same radiopharmaceutical [19–24]. More-
over, with its congener 67Cu (t1/2 = 61.5 h, ß
− 100 %,
Emean = 0.121 MeV), a therapeutic copper isotope is avail-
able allowing theranostic applications [25].
Recently, we showed that the series of TACN-based
chelators NOTI 1, NOTI-Me 2, and NOTThia has excellent
complexation properties for coordination of 64Cu2+ cations
[17]. In extensive labeling experiments, these ligands
demonstrated rapid complexation kinetics over a wide pH
range of 4.0 to 8.0 providing quantitative radiochemical
conversions under very mild conditions (G 5min incubation
time, room temperature). Corresponding 64Cu complexes
were obtained in high molar activities of 120–
180 MBq nmol−1. In ligand challenge, copper exchange,
and PET imaging experiments in mice, 64Cu complexes also
demonstrated high kinetic inertness in vitro and in vivo.
According to single crystal X-ray analyses of corresponding
copper complexes, these excellent complexation properties
are the result of the interplay between the optimal ring size
of the TACN macrocycle and the pronounced affinity of
divalent copper for the azaheterocyclic N donors. However,
these ligands lacked a functionality that allowed their
conjugation to target-specific biomolecules. As a conse-
quence, the BFC NODIA-Me 3 (2-(4,7-bis((1-methyl-1H-
imidazol-2-yl)methyl)-1,4,7-triazonan-1-yl)acetic acid),
depicted in Scheme 1, was developed, in which one of the
heterocyclic arms was replaced with an acetic acid group to
serve as the site for the attachment of various targeting
vectors. In subsequent studies, NODIA-Me 3 was success-
fully conjugated to a prostate-specific membrane antigen
(PSMA) targeting vector [26]. In a more recent study using
68Ga- and 64Cu-labeled PSMA-targeting conjugates com-
prising NODIA-Me 3, the applicability of this BFC in
radiopharmaceutical development was successfully demon-
strated [27]. Corresponding 68Ga- and 64Cu-labeled NODIA-
Me-PSMA conjugates specifically delineated PSMA-
positive LNCaP tumors with low background accumulation
in small-animal PET imaging experiments and ex vivo
biodistribution studies [27]. Noteworthy, no significant
decomplexation/transchelation of the radiometal chelate
was noted in vitro (G 2 % transchelation in copper exchange
experiments over 24 h) and in vivo by PET imaging in
healthy mice (rapid clearance with 1h post injection),
underscoring the use of our chelating platform for radio-
pharmaceutical applications.
An intriguing finding of our previous studies was that
modifications at the non-coordinating NH atoms of imidaz-
ole residues, e.g., NOTI 1 vs. NOTI-Me 2, did not alter the
metal binding properties to a measurable extent [17]. This
may offer the possibility of introducing additional function-
alities to the metal chelator without compromising its
complexation properties, potentially making the NOTI 1
scaffold a versatile tool for radiopharmaceutical develop-
ment. To investigate this in more detail, we designed a
trifunctional NOTI-TVA 6 building block with three
additional carboxylic acid groups for the covalent conjuga-
tion of three targeting vectors via peptide bond formation.
The primary aims of this proof-of-concept study were (1) to
evaluate if trimeric radiotracers on the basis of the NOTI-
TVA 6 scaffold can be developed, (2) to determine if the
additional substituents for bioconjugation at the non-
coordinating NH atoms of the imidazole residues of the
building block NOTI influence the metal binding properties,
and (3) what influence multiple targeting vectors have on the
biological performance of the radiotracer. For this purpose, a
trimeric c(RGDfK) conjugate was subsequently prepared on
the basis of the NOTI-TVA scaffold 6. Here, we report the
64Cu-labeling and preclinical evaluation of the trimeric
c(RGDfK) bioconjugate in vitro and in vivo and provide a
direct comparison to the monomeric counterpart. The
c(RGDfK) targeting vector was chosen as a model for this
proof-of-principle study since multiple multimeric radio-
tracers comprising two or more RGD targeting vectors have
been thoroughly investigated due to the low expression of
the corresponding αvß3 integrin receptor. The results of this
proof-of-concept study suggest that NOTI 1 is an ideal
building block for the development of multifunctional
radiotracers, considerably broadening the application scope
of our chelating platform.
Methods
General
Chemicals and solvents were purchased from Sigma-Aldrich
and TCI Europe, and used as received. The bifunctional
chelator NODIA-Me 3 was prepared as previously described
[28, 29]. The peptide c(RGDfK) 7 was purchased from ABX
(Radeberg, Germany). The radioligand [125I]I-echistatin was
obtained from Perkin Elmer (Boston, USA). High-resolution
mass spectrometry ((+)-HR-ESI-MS) was performed on a
Thermo Scientific Exactive mass spectrometer. [64Cu]CuCl2
was purchased from the Department of Preclinical Imaging
and Radiopharmacy of the Eberhard-Karls-University
(Tübingen, Germany). [64Cu]CuCl2 was produced via the
64Ni(p,n)64Cu route [30]. The corresponding molar activity
was Am = 300–400 MBq/nmol (18 h EOB). Proton NMR
spectra were measured in MeOD or CDCl3 at room
temperature using a Bruker DRX Avance 250 MHz NMR
spectrometer. Chemical shifts are given in parts per million
(ppm) and are reported relative to trimethylsilane (TMS).
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Coupling constants are reported in hertz (Hz). The multi-
plicity of the NMR signals is described as follows: s =
singlet, d = duplet, t = triplet, q = quartet, m = multiplet.
High-performance liquid chromatography (HPLC) was
performed on an Agilent 1260 Infinity System equipped
with an Agilent 1200 DAD UV detector (UV detection at
220 nm) and a Raytest Ramona radiation detector (Raytest
GmbH, Straubenhardt, Germany) in series. A Phenomenex
Jupiter Proteo (250 × 4.60 mm) column was used for
analytical HPLC. The solvent system was A = H2O (0.1 %
TFA) and B = acetonitrile (0.1 % TFA). The gradient was 0–
1 min 5 % B, 1–25 min 50 % B, 25–27 min 95 % B, 27–
29 min 95 % B, 29–32 min 5 % B, and 32–35 min 5 % B at
a flow rate of 1 ml min−1. Semi-preparative HPLC was
performed on a Knauer Smartline 1000 HPLC system in
combination with a Macherey Nagel VP 250/21 Nucleosil
120-5 C18 column. Semi-preparative HPLC gradient was 0–
40 min 5–60 % B at a flow rate of 12 ml min−1. For
automated flash chromatography, a Biotage Isolera Four
system was used. Normal phase chromatography was carried
out by using a SNAP KP-Sil (50 g) column and n-hexane
(D)/ethyl acetate (E) as eluents. The flow rate was 50 ml
min-1. Detection wavelength was set at 280 nm. The normal
phase gradient was 3 CVs (cartridge volumes) 0 % E, 3 CVs
to 100 % E, and 4 CV 100 % E. Reverse phase flash
chromatography was conducted with a SNAP Ultra C18
(30 g) cartridge. The solvent system was A = H2O and B =
acetonitrile (both 0.1 % TFA). The flow rate was set at
25 ml min−1 with a detection wavelength of 280 nm. The
reversed phase gradient was 2 CVs 0 % B, 6 CVs 100 % B,
and 2 CVs 100 % B. Samples were lyophilized using a
Christ Alpha 1-2 LD plus lyophilizer. All instruments
measuring radioactivity were calibrated and maintained in
accordance with previously reported routine quality control
procedures [31]. Radioactivity was measured using an
Activimeter ISOMED 2010 (Nuklear-Medizintechnik, Dres-
den, Germany). For accurate quantification of radioactivity,
experimental samples were counted for 1 min on a calibrated
Perkin Elmer (Waltham, MA, USA) 2480 Automatic Wizard
Gamma Counter by using a dynamic energy window of
400–600 keV for copper-64 (511 keV emission). Statistical
analyses (two-tailed Student’s t test, confidence interval
95 %) were performed using GraphPad Prism Version 7.0.
Chelator and Bioconjugate Syntheses
Preparation of NOTI-TVA 6 Route A: The NOTI 1
chelator was prepared as previously described in 17 %
yield [17]. NOTI·3TFA (200 mg, 0.28 mmol) was
reacted with methyl-5-bromovalerate (950 mg,
4.87 mmol) and cesium hydroxide hydrate (1.82 g,
10.8 mmol) in 25 ml of N,N-dimethylformamide (DMF)
for 2 h at room temperature. After azeotropic removal of
the DMF by co-evaporation with 5 × 50 ml toluene, the
reaction mixture was acidified by addition of trifluoro-
acetic acid (TFA) until pH ~ 2 was achieved and further
purified by reversed phase automated flash chromatogra-
phy using C18 SNAP cartridges. The NOTI-TVA methyl
ester 5 (280 mg, 0.27 mmol) was obtained as triple
triflate salt in 65 % yield. Hydrolysis of methyl esters
was achieved by heating compound 5 for 2 h at 95 °C in
10 ml of a H2O/TFA mixture (1:9, v/v) to give NOTI-
TVA 6 (288 mg, 0.26 mmol) in quantitative yields.
Methyl 5-(2 formyl-1H-imidazol-1-yl)pentanoate 4 Route
B: Imidazole-2-carboxyaldehyde (3.0 g, 3.31 mmol),
methyl-2-bromovalerate (5.34 ml, ρ = 1.363 g ml−1,
3.76 mmol), and potassium carbonate (8.62 g, 6.26 mmol)
were mixed in 30 ml acetonitrile. The reaction was stirred
for 24 h at 45 °C. Insoluble salts were filtered off and the
brown liquid was concentrated by rotary evaporation to a
volume of ~ 5 ml for the subsequent flash chromatography.
Automated normal phase flash chromatography was applied
for purification. The product 4 was obtained as colorless oil.
Yield: 4.03 g, 19.1 mmol, 61 %. 1H-NMR (CDCl3): δ = 9.76
(s, 1H), 7.24 (d, J = 1.88 Hz, 1H), 7.14 (d, J = 1.9 Hz, 1H),
4.36 (t, J = 7.4 Hz, 2H), 3.62 (s, 3H), 2.31 (t, J = 7.0 Hz,
2H), 1.78 (m, 2H), 1.61 (m, 2H). HR-ESI-MS: calc. for
C10H15N2O3 ([M + H]
+): 211.1083, found: 211.1075. RP-
HPLC (analytical): tR = 9.2 min, purity 9 99 %.
Trimethyl-5,5′,5″-(((1,4,7-triazonane-1,4,7-triyl)tris(methy-
lene))tris(1H-imidazole-2,1-diyl))tripentanoate 5 1,4,7-
Triazacyclononane (200 mg, 1.55 mmol) and compound 4
(1.71 g, 7.74 mmol) were dissolved in 10 ml THF and the
reactants heated at 70 °C for 24 h during the reaction
solution became yellowish in color. After cooling to room
temperature, sodium triacetoxyborohydride (2.0 g,
9.43 mmol) was added stepwise (300 mg every 30 min).
After 5 h, 50 ml MeOH was added and the solvents were
removed under reduced pressure generating a yellow oil.
This was dissolved in 10 ml of a H2O/ACN (2:1, v/v) and
the pH of the solution was carefully adjusted with TFA to
pH 2–3. The crude mixture was purified by reversed phase
automated flash chromatography. Fractions containing the
product were combined and the solvents removed by rotary
evaporation to give 5 as yellowish oil. Yield: 1.044 g,
1.47 mmol, 95 %. 1H-NMR (MeOD): δ = 7.61 (d, J =
1.44 Hz, 3H), 7.54 (d, J = 1.44 Hz, 3H), 4.37 (s, 6H), 4.18 (t,
J = 5.86 Hz, 6H), 3.65 (s, 9H), 3.13 (s, 12H), 2.40 (t, J =
5.74 Hz, 6H), 1.82 (m, 6H), 1.61 (m, 6H). HR-ESI-MS:
calc. for C36H58N9O6 ([M + H]
+): 712.4505, found:




6 For the hydrolysis of methyl esters, compound 5
(100 mg, 0.14 mmol) was heated at 95 °C for 24 h in 5 ml
H2O/TFA (1:1, v/v). Solvents were removed under reduced
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pressure and the product lyophilized to obtain compound 6.
Yield: 93.6 mg, 0.14 mmol, quantitative. 1H NMR (MeOD):
δ 7.61 (d, J = 1.68 Hz, 3H), 7.54 (d, J = 1.72 Hz, 3H), 4.42
(s, 6H), 4.23 (t, J = 7.3 Hz, 6H), 3.15 (s, 12H), 2.40 (t, J =
7.06 Hz, 6H), 1.90 (m, 6H), 1.64 (m, 6H). HR-ESI-MS:
calc. for C33H52N9O6 ([M + H]
+): 670.4035, found:
670.4042. RP-HPLC (analytical): tR = 10.5 min, purity 9
99 %.
NODIA-Me-c(RGDfK) 8 The monomer 8 (Scheme 2) was
prepared as previously described and characterization data
was identical to that previously reported [29].
NOTI-TVA-c(RGDfK)3 9 NOTI-TVA 6 (2 mg,
0.003 mmol), HATU (1-[bis(dimethylamino)methylene]-
1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluoro-
phosphate) (4 mg, 0.011 mmol), and DIPEA (N,N-
diisopropylethylamine) (5.8 mg, 8 μl, 0.045 mmol) were
mixed in 500 μl anhydrous DMF and allowed to stir for
30 min at room temperature. Next, the peptide c(RGDfK) 7
(6.3 mg, 0.009 mmol) in 100 μl DMF was added and
stirring was continued for an additional 2 h. The solvent
was removed by rotary evaporation and the residue was
taken up in water/acetonitrile (50:50 v/v) with 0.1 % TFA
and purified by semi-preparative HPLC. Fractions contain-
ing the product were combined and lyophilized to give
compound 9 as white powder (3.0 mg, 0.001 mmol, 41 %).
HR-ESI-MS calcd m/z for C114H170N36O24 ([M + 2H]
2+):
1213.6578, found: 1213.6595. RP-HPLC (analytical): tR =
16.5 min. RP-HPLC (semi-preparative): tR = 18.0 min.
Preparation of Copper Reference Compounds
(Cu-8 and Cu-9)
From aqueous stock solutions of each bioconjugate (each
1 nmol μl−1), 500 μl were mixed with 500 μl of an
aqueous CuCl2 stock solution (2 nmol μl
−1) and the
mixture heated at 95 °C for 15 min. After cooling to r.t.,
the complexes were purified using C18 Sep-Pak car-
tridges, which were preconditioned with each 5 mL of
H2O and EtOH, respectively. After loading, the car-
tridges were washed with 2 ml H2O and the products
were eluted using 2 ml EtOH:H2O (50:50 v/v). After
evaporation of EtOH at ambient temperature, the remain-
ing solutions were lyophilized to give Cu-8 (450 μg,
0.44 μmol, 88 %) and Cu-9 (1157 μg, 0.47 μmol, 93 %)
as white powders. RP-HPLC (analytical) Cu-8: tR =
15.7 min. HR-ESI-MS calcd m/z for C45H68N16O8Cu
([M]2+): 511.7351, found: 511.7348; RP-HPLC




Radiolabeling of [64Cu]Cu-8 and [64Cu]Cu-9
Radiolabeling of 8 and 9 with [64Cu]CuCl2 was performed
manually. In a typical labeling reaction, to solution of
450 μl, 0.5 M ammonium acetate (pH 8.2) was added 20 μl
of the corresponding conjugate stock solution (1 nmol μl−1)
followed by the addition of 200 MBq [64Cu]CuCl2 in 30 μl
0.1 M hydrochloric acid. Directly after the addition of the
radioactivity, a sample of the labeling solution was analyzed
by HPLC. The radiochemical purities (RCPs) and yields
(RCYs) of both conjugates were always ≥ 99 %. The mean
molar activities for both compounds were Am ~
20 MBq nmol−1 (each n = 5). RP-HPLC (analytical, radio-
activity detector): tR ([
64Cu]Cu-8) = 16.3 min; tR ([
64Cu]Cu-
9) = 18.7 min.
Lipophilicity (Log Doct/PBS) Measurements
For log Doct/PBS measurements, 1–2 MBq of [
64Cu]Cu-8 and
[64Cu]Cu-9 in 5 μl labeling buffer were added to a mixture
of phosphate-buffered saline pH 7.4 (PBS) (495 μl) and
octanol (500 μl). Samples were shaken for 30 min at room
temperature, centrifuged at 13,200 rpm for 5 min, and 100 μl
of each phase was counted using a gamma counter. Experi-
ments were performed in triplicate.
Serum Stability Measurements
For each experiment, ~ 5 MBq (10 μl) of [64Cu]Cu-8 and
[64Cu]Cu-9 was added to human serum (490 μl, human
male AB plasma, Sigma-Aldrich), which was pre-
equilibrated at 37 °C in a cell incubator for 1 h. Samples
were vortexed briefly and stored at 37 °C in a cell
incubator. At selected time points, aliquots of 100 μl were
taken from the serum solution and serum proteins
removed by centrifugation using centrifuge tubes (molec-
ular weight cutoff 30 kDa) at 4 G for 5 min at 4 °C. One
hundred microliters of PBS were added to the filter
followed by an additional centrifugation step. The
corresponding filtrates were analyzed by HPLC. The
percentage of intact [64Cu]Cu-8 and [64Cu]Cu-9 was
calculated from the HPLC chromatograms. All experi-
ments were performed in triplicate.
Cell Culture
U-87MG cells (ATCC, Manassas, VA, USA) were
cultured at 37 °C in a 5 % CO2 atmosphere (Dulbecco
modified Eagle medium with GlutaMAX containing
10 % fetal bovine serum, 1 % 10,000 U ml−1 penicillin
and 10,000 U ml−1 streptomycin, 1 % sodium-pyruvate
100 mM).
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Competitive Binding Assay
The binding affinity of Cu-8 and Cu-9 was determined by a
cell-based competitive binding assay in the human glioma
cell line U-87MG with [125I]I-echistatin as the radioligand as
previously described [32]. Binding assays were performed in
24-well plates precoated with poly-L-lysine. Briefly, each
compound at different concentrations (0–10,000 nM) was
incubated for 2 h at r.t . with [125I]I-echistatin
(30,000 cpm well−1) and 2 × 105 U-87MG cells well−1.
After incubation, cells were washed three times with ice-cold
binding buffer and cell-associated activity recovered by
addition of 1 M NaOH. Radioactivity was measured by a
gamma counter and data fitted using non-linear regression
(GraphPad Prism). Experiments were performed two times
in triplicate.
Cell Internalization Assay
For cell internalization, U-87MG cells were seeded at a
density of 106 cells per well in 6-well plates and incubated
overnight with medium (Dulbecco modified Eagle medium
with GlutaMAX containing 10 % fetal bovine serum, 1 %
10,000 U ml−1 penicillin and 10,000 U ml−1 streptomycin,
1 % sodium-pyruvate 100 mM). After 24 h, the medium was
removed and the cells were washed with PBS. Approxi-
mately 2.5 pmol of [64Cu]Cu-8 and [64Cu]Cu-9 was added
to the cells (in triplicates) to give a final volume of 1.5 ml
PBS in each well followed by incubation for 1 h at 37 °C,
5 % CO2. To determine non-specific membrane binding and
internalization, excess of c(RGDfK) (final concentration
1 μM) was added to selected wells. At each time point, the
internalization was stopped by removing the medium and
washing the cells twice with ice-cold PBS. To remove the
receptor-bound radioligand, an acid wash was carried out
twice with a 0.1 M glycine buffer pH 2.8 for 5 min on ice.
Finally, cells were solubilized with 1 N NaOH. Radioactiv-
ity of cell fractions (supernatant, receptor-bound, and
internalized) was measured by a Perkin Elmer gamma
counter. Experiments were performed twice in triplicate.
Small-Animal PET Imaging
All animal experiments complied with the current laws of
the Federal Republic of Germany and were conducted
according to German Animal welfare guidelines. Normal
female athymic Balb/c nude mice (17–20 g, 4–6 weeks old)
were obtained from Janvier SAS (St. Berthevin Cedex,
France). Mice were provided with food and water ad libitum.
U-87MG tumors were induced on the right shoulder by sub-
cutaneous injection of 5 × 106 cells in a 100 μl cell
suspension of a 1:1 v/v mixture of media with reconstituted
basement membrane (GFR BD Matrigel™, Corning BV,
Amsterdam, Holland).
Static and dynamic PET imaging experiments were
conducted on a microPET Focus 120 scanner (Concorde
Microsystems) [33]. For dynamic PET imaging studies,
approximately 5 min prior to recording PET images,
mice (n = 3) were anesthetized by inhalation of 2–3 %
isoflurane/oxygen gas mixture, fitted with an intravenous
catheter and placed on the scanner bed in the prone
position. Anesthesia was maintained using 1–2 % iso-
flurane. For all experiments, animals were injected with
100 μl sterile filtered phosphate-buffered saline formula-
tions pH 7.4 of [64Cu]Cu-8 and [64Cu]Cu-9 (~ 500 pmol,
7–11 MBq). Dynamic scans were recorded from 0 to 1 h
post radiotracer administration. List-mode data were
acquired using a γ-ray energy window of 350–650 keV
and a coincidence timing window of 6 ns. For the 24 h
p.i. time point, mice were injected 24 h prior to image
acquisition and placed in the cages. Five to ten minutes
prior to static PET imaging, mice were anesthetized with
isoflurane (2–4 % in air) and positioned in the scanner.
Animals of the PET imaging studies were included in the
ex vivo biodistribution studies (vide infra). Reconstruc-
tion was performed using unweighted OSEM2D. Image
analysis was performed using AMIDE. Image counts per
second per voxel (cps/voxel) were calibrated to activity
concentrations (Bq ml−1) by measuring a 3.5-cm cylinder
phantom filled with a known concentration of radioac-
tivity. Specificity of [64Cu]Cu-8 and [64Cu]Cu-9 was
confirmed by competitive inhibition (blocking) by co-
injecting the peptide c(RGDfK) 7 (20 nmol mouse−1;
n = 3).
Ex Vivo Biodistribution
For each compound, a total of three animals were injected
with [64Cu]Cu-8 and [64Cu]Cu-9 (~ 500 pmol, 7–11 MBq)
in 100 μl sterile filtered phosphate-buffered saline via a tail
vein. At 1 h p.i., animals were sacrificed by isoflurane
anesthesia. Organs of interest were dissected, weighed, and
assayed for radioactivity in a gamma counter. The percent
injected activity per gram (%IA g−1) for each tissue was
calculated by comparison of the tissue counts to a standard
sample prepared from the injectate. Specificity of [64Cu]Cu-
8 and [64Cu]Cu-9 was determined by co-injection of the
peptide c(RGDfK) 7 (20 nmol mouse−1).
Results
Chelator and Bioconjugate Synthesis
To introduce additional functional groups to the NOTI 1
chelator for bioconjugation, two synthetic routes were
explored (Scheme 3). Initially, the preparation of the
trifunctionalized derivative started with the synthesis of
NOTI 1 by reacting the 1,4,7-triazacyclononane (TACN)
macrocycle with imidazole-2-carboxaldahyde and sodium
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borohydride in basic aqueous medium as previously de-
scribed (route A) [17]. Under these reaction conditions, a
mixture of di- and trisubstituted TACN was obtained
providing the corresponding compounds di- and triderivat-
ized compounds NODI and NOTI 1 in 46 % and 17 % yield,
respectively. The NOTI 1 chelator then served as a building
block for the preparation of the corresponding triply
functionalized derivative NOTI-TVA 6. The introduction
of additional carboxylic acid functionalities for bioconjuga-
tion was achieved by reacting NOTI 1 with methyl-5-
bromovalerate in the presence of cesium hydroxide in N,N-
DMF at 60 °C for 2 h. This way, the triply derivatized
NOTI-TVA (trivaleric acid) methyl ester 5 was obtained in
65 % yield. Subsequent hydrolysis of corresponding methyl
esters in a H2O/TFA mixture at 95 °C for 2 h gave the
NOTI-TVA 6 building block in 11 % overall yield.
In route B, the imidazole-2-carboxaldehyde was derivat-
ized with methyl-5-bromovalerate prior to reacting with the
TACN macrocycle. Reaction of the aldehyde with methyl-5-
bromovalerate and potassium carbonate in N,N-DMF for
24 h at 45 °C (Scheme 3) proceeded smoothly and provided
compound 4 in 61 % yield. NOTI-TVA methyl ester 5 was
prepared by reductive amination in THF using sodium
triacetoxyborohydride in 95 % yield. Noteworthy, under
these conditions, only the triply derivatized NOTI-TVA
methyl ester 5 was obtained. Removal of the methyl esters
was achieved again with 5 M hydrochloric acid providing
the NOTI-TVA 6 scaffold in 58 % overall yield.
The homotrimeric NOTI-TVA-c(RGDfK)3 bioconjugate
8 was prepared by reacting NOTI-TVA 6 with 3.5
equivalents of the commercially available c(RGDfK) peptide
7 in the presence of HATU (O-(7-azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium-hexafluorphosphat) and N,N-
diisopropylethylamine (DIPEA) in DMF (Scheme 4). After
purification by semi-preparative HPLC, the final bioconju-
gate NOTI-TVA-c(RGDfK)3 9 was successfully obtained in
41 % yield. Corresponding characterization data of inter-
mediates and bioconjugates including NMR, MS, and HPLC
data are provided as Electronic Supplementary Material. For
comparison reasons (vide infra), the monomeric compound
NODIA-Me-c(RGDfK) 8 was prepared as previously
reported and included in this study (Scheme 3) [29].
64Cu-Labeling and Characterization In Vitro
Both the monomer NODIA-Me-c(RGDfK) 8 and the
trimer NOTI-TVA-c(RGDfK)3 9 were labeled manually
with [64Cu]CuCl2 in 0.5 M ammonium acetate (pH 8.2).
Quantitative radiochemical yields were achieved for both
conjugates at room temperature in less than 5 min of
incubation time. Radiolabeling conditions were chosen to
obtain both tracers in molar activities of ~ 20 MBq nmol
−1. Corresponding radiochemical purities (RCP) were ≥
99 % for both compounds. Both radiolabeled compounds
gave a single radioactive peak in the analytical HPLC
and their identity was confirmed using their non-
radioactive reference counterparts (Figs. S10+11). In
serum stability studies, no demetalation or other metab-
olites were detected up to 24 h by radio-HPLC.
Corresponding log Doct/PBS values of [
64Cu]Cu-8 and
[64Cu]Cu-9 were − 3.69 ± 0.15 and − 3.14 ± 0.12,
respectively.
The binding affinity of Cu-8 and Cu-9 to the αvß3 integrin
receptor was evaluated by competitive cell binding experi-
ments in the αvß3-positive U-87MG glioblastoma cell line.
Both compounds inhibited the binding of [125I]I-echistatin in
a dose-dependent manner (Fig. 1a) and corresponding IC50
values for c(RGDfK) 7, Cu-8, and Cu-9 were determined to
be 159.5 ± 1.3 nM, 256.1 ± 2.1 nM, and 99.5 ± 1.1 nM,
respectively. In addition to the inhibitory binding constants,
the receptor-mediated internalization of [64Cu]Cu-8 and
[64Cu]Cu-9 in U-87MG cells was also evaluated over a 4-
h time period (Fig. 1b). Both compounds showed a gradually
increasing receptor-mediated internalization over time. For
the monomer [64Cu]Cu-8, an αvß3-specific increase in
internalization from 0.2 ± 0.1 % after 30 min to 1.4 ± 0.1 %
at 4 h was noted, whereas the trimer [64Cu]Cu-9 exhibited an
increased internalization with 0.7 ± 0.2 % after 30 min and
8.7 ± 0.6 % after 4 h. In fact, the trimer displayed a
significantly higher internalization than the monomer at later
time points (2 h, P = 0.016; 4 h, P = 0.004) being in
accordance with the results of the competitive binding
experiment. On the other hand, the specific surface-bound
fraction for [64Cu]Cu-8 and [64Cu]Cu-9 was low with ≤
0.1 % at all time points.
Scheme 2 Two synthetic routes for the preparation of the trifunctionalized NOTI-TVA 6 scaffold.
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Ex Vivo Biodistribution and Small-Animal PET
Imaging
The biodistribution for [64Cu]Cu-8 and [64Cu]Cu-9 was
assessed in female BALB/c mice bearing U-87MG xeno-
grafts. A graphical representation of the results of the ex vivo
biodistribution study including blockade at 1 h post-injection
(p.i.) are given in Fig. 2. Data is provided in tabular form as
Electronic Supplementary Material (Table S1).
In accordance with the results of the cell experiments, the
trimer [64Cu]Cu-9 exhibited a significantly higher tumor
uptake than the monomer [64Cu]Cu-8 with 2.30 ±
0.28 %IA g−1 and 5.57 ± 0.83 %IA g−1 at 1 h p.i. (P =
0.003), respectively. Target specificity was confirmed by co-
injection of c(RGDfK) 7, which significantly reduced the
uptake in U-87MG xenografts by 89 % (P = 0.0002) and
60 % (P = 0.002) for [64Cu]Cu-8 and [64Cu]Cu-9, respec-
tively. The highest tracer accumulation for [64Cu]Cu-9 was
observed in the liver with 5.63 ± 1.61 %IA g−1 and the
kidneys with 7.65 ± 0.52 %IA g−1, suggesting excretion of
the tracer via the hepatobiliary and renal pathway. Kidney
and liver uptakes were blockable with 3.32 ± 0.09 %IA g−1
(P = 0.0084) and 5.45 ± 0.59 %IA g−1 (P = 0.1038), respec-
tively, indicating that accumulation in both organs was also
Scheme 3 Synthetic scheme for monomeric bioconjugate NODIA-Me-c(RGDfK) 8
a b
Fig. 1. a Competitive inhibition of [125I]I-echistatin by c(RGDfK) 7, Cu-8 and Cu-8 in the U-87MG cell line. b Receptor-
mediated internalization of [64Cu]Cu-8 and [64Cu]Cu-9 into U-87MG cells over time.
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partially receptor mediated. Radiotracer accumulation in the
blood at 1 h p.i. was low for both compounds with 0.16 ±
0.05 %IA g−1 for the monomer and 0.34 ± 0.05 %IA g−1 for
the trimer, resulting in high tumor-to-blood ratios of 14.37
and 16.38, respectively.
The pharmacokinetic profiles of 64Cu-labeled 8 and 9
were also determined by small-animal PET imaging.
Dynamic PET imaging in BALB/c mice bearing U-87MG
xenografts, along with blocking studies, was performed for
1 h after radiotracer administration. An additional static PET
scan was performed at 24 h p.i. Corresponding transverse
and coronal PET images of [64Cu]Cu-8 and [64Cu]Cu-9 are
given in Figs. 3 and 4, respectively. Tumor uptakes of
[64Cu]Cu-8 and [64Cu]Cu-9 at 1 h p.i. was 2.61 ±
0.65 %IA cm−3 and 4.42 ± 1.10 %IA cm−3, respectively.
Target specificity was confirmed by co-injection of
c(RGDfK) (5 mg/kg) resulting in a significant reduction of
tumor accumulation with 0.91 ± 0.39 %IA cm−3 and 2.18 ±
0.66 %IA cm−3 for [64Cu]Cu-8 and [64Cu]Cu-9 as well as
reduced uptake in all other organs.
Discussion
For this proof-of-principle study, the cyclic RGDfK 7
peptide was selected as the targeting vector which binds
specifically to the αvß3 integrin receptor. The integrin αvß3
receptor is upregulated in activated endothelial cells of
tumors undergoing angiogenesis but is not expressed in
normal cells and quiescent vessel cells making it a key target
for the diagnosis of malignant tumors and metastases [34,
Scheme 4 Preparation of trimeric bioconjugate NOTI-TVA-c(RGDfK)3 9.
a b
Fig. 2. Ex vivo biodistribution data for [64Cu]Cu-8 (a) and [64Cu]Cu-9 (b) in female U-87MG xenograft bearing BALB/c mice at
1-h post-injection including blockade. Data given as percent injected activity per gram ± standard deviation (%IA g−1 ± SD).
Statistical significance between the normal and blocking groups was determined by an unpaired two-tailed t test and is
indicated by an asterisk (P G 0.05).
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35]. Besides applications in oncology, imaging of αvß3
expression is also applied in cardiology and inflammatory
diseases [36, 37]. Due to the low expression profile of the
αvß3 integrin receptor, this peptide/receptor couple was one
of the first systems for which multimeric/multivalent radio-
tracers were developed in order to increase the tumor uptake
by making use of the multivalency effect [12, 13, 16, 38–
40]. This seemed to be the appropriate biological system to
evaluate the potential of our chelating platform since up to
three targeting vectors can potentially be covalently conju-
gated to the NOTI-TVA scaffold 6 via peptide bond
formation.
In order to establish a reliable synthetic route for the
chelator scaffold, the two synthetic pathways for the
preparation of the NOTI-TVA 6 were explored. The initial
synthesis started with the recently described chelator NOTI 1
to which valeric acid residues were introduced via nucleo-
philic substitution. However, the overall yield of route A
(11 %), depicted in Scheme 3, was quite low being a result
of the low yielding synthesis of NOTI 1 due to the very
limited solubility, and thus limited reactivity of the
imidazole-2-carboxaldehyde in organic solvents and aque-
ous media [17]. On the other hand, the introduction of the
valeric acid residues and the subsequent cleavage of
a b c d
Fig. 3. Representative transverse and coronal PET images of [64Cu]Cu-8 in female U-87MG xenograft bearing BALB/c mice at
1 and 24 h (a + c) post-injection including blockade by co-injection of c(RGDfK) (b + d).
Fig. 4. Representative transverse and coronal PET images of [64Cu]Cu-9 in female U-87MG xenografts bearing BALB/c mice
at 1 and 24 h (a + c) post-injection including blockade by co-injection of c(RGDfK) (b + d).
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corresponding methyl esters proceeded smoothly in quanti-
tative yields. This straightforward and high yielding deriv-
atization of imidazoles led to the exploration of an
alternative synthetic route (route B) to obtain the NOTI-
TVA 6 scaffold in higher overall yields (Scheme 3). Here,
the imidazole carboxaldehyde was derivatized with valeric
acid prior to reacting with the TACN macrocycle. The
functionalization of the NH group of the imidazolecarbox-
aldehyde significantly increased its solubility and reactivity
in organic solvents resulting in a fivefold improvement in
overall yield (58 %) in comparison with route A (overall
yield 11 %). This approach provides access to the NOTI-
TVA 6 scaffold in high yield but, more importantly, also
nicely demonstrates the potential and flexibility of the NOTI
chelating platform. The possibility to straightforwardly
derivatize the imidazole residues by nucleophilic substitution
allows the development of various functionalized NOTI
derivatives including other bioconjugation strategies in high
yield for future studies. The corresponding NOTI-TVA-
c(RGDfK)3 9 conjugate for this proof-of-principle study was
prepared by standard peptide chemistry demonstrating that
homotrimeric compounds based on the NOTI-TVA 6
scaffold are readily accessible by this approach. In subse-
quent 64Cu-labeling experiments and serum stability studies,
no significant differences in terms of radiolabeling and
in vitro stability compared with the non-derivatized chelators
were noted suggesting that the additional valeric acid
substituents are well tolerated in terms of metal chelation
[17].
Moreover, we were interested in the influence of the
metal chelates on the lipophilicity of corresponding bio-
conjugates to elucidate if a central chelating unit is a feasible
approach for the development of multimeric/multivalent
radiotracers. As a measure of lipophilicity, corresponding
partition coefficients log Doct/PBS were determined for the
64Cu-labeled monomer and trimer. The 64Cu-labeled mono-
mer 8 was only slightly more lipophilic than its 68Ga-labeled
counterpart [68Ga]Ga-8 with a log Doct/PBS of − 3.89 ± 0.02
[29]. In line with the HPLC retention times, the 64Cu-labeled
trimer 9 was only minimally more lipophilic than the
monomer 8 despite its relatively high molecular weight in
comparison with the monomer 8 (961 g mol−1vs. 2426 g mol
−1). Noteworthy, the 64Cu-labeled trimer 9 was more
hydrophilic than other monomeric RGD radiotracers such
as [64Cu]Cu-CB-TE2A-c(RGDfK), [64Cu]Cu-NODAGA-
c(RGDfK), and [64Cu]Cu-DOTA-c(RGDfK) with log Doct/
PBS of − 2.92, − 2.76, and − 2.77, respectively [32]. This may
be a consequence of the high hydrophilicity of 64Cu chelates
of NOTI 1, NOTI-Me 2, and NOTThia, making them ideal
candidates for increasing the overall hydrophilicity of
lipophilic targeting vectors [17]. The results also suggest
that connecting multiple targeting vectors via a central metal
binding moiety as it is the case for the NOTI-TVA scaffold 6
may be superior to other approaches in which multiple
targeting vectors/biomolecules are connected via aliphatic
linkers and, then, conjugated terminally to the metal chelator
or 18F-radiolabeled prosthetic group. This approach has been
commonly used for many metal chelators, e.g., DOTA or
NOTA, or other radiolabels due to their limited number of
functionalities for bioconjugation often only allowing the
conjugation of a single biomolecule [9–16].
To study the effect of multiple RGD targeting vectors on
the target binding, the binding affinity of Cu-8 and Cu-9 to
the αvß3 integrin receptor was evaluated by competitive cell
binding experiments in the αvß3-positive U-87MG glioblas-
toma cell line. For the monomer Cu-8, the introduction of
the NODIA-Me chelate to the peptide had only a minimal
effect on receptor binding as already seen for the
corresponding Ga-8 monomer with an IC50 = 205.1 ±
1.4 nM [29]. Interestingly, the trimeric compound Cu-9
displayed an increased binding affinity compared with the
Ga-8 and Cu-8 monomers suggesting that multimerization of
targeting vectors using the NOTI platform may result in
higher binding affinity. Given the short distance between the
c(RGDfK) peptide residues (∼ 20 bond distances) of the
trimer, it is unlikely that they would bind simultaneously to
adjacent αvß3 integrin receptors to achieve a multivalency
effect. However, the binding of one c(RGDfK) motif to the
receptor significantly increases the “local concentration” in
the vicinity of the receptor binding site. This might lead to
an enhanced αvß3 integrin binding rate or a reduced
dissociation rate of the c(RGDfK) peptide from the αvß3
integrin receptor. Even though a direct comparison to other
studies is not possible due to differences in the experimental
design, e.g., different cell line, the determined IC50 values
are in accordance with those of previously reported
monomeric RGD radiotracers [32]. The receptor-mediated
internalization of [64Cu]Cu-8 and [64Cu]Cu-9 was further-
more evaluated for up to 4 h. Cellular internalization upon
receptor binding is believed to translate into prolonged
tumor retention in vivo. Both radiotracers were specifically
internalized with the [64Cu]Cu-9 trimer exhibiting a signif-
icantly higher internalization than the monomer being in
accordance with the results of the competitive binding
experiment. In summary, a higher binding affinity as well
as specific cellular internalization was noted for the trimer in
comparison with its monomeric counterpart suggesting that
the use of several targeting moieties based on the NOTI-
TVA chelating platform may lead to superior tumor binding
and accumulation.
To elucidate if the higher binding affinity and cellular
internalization of the trimer translated to an increased tumor
uptake in vivo, we assessed the biodistribution for [64Cu]Cu-
8 and [64Cu]Cu-9 in female BALB/c mice bearing U-87MG
xenografts. Indeed, the trimer [64Cu]Cu-9 exhibited a
significantly higher tumor uptake than the monomer
[64Cu]Cu-8 with 2.30 ± 0.28 %IA g−1 and 5.57 ±
0.83 %IA g−1 at 1 h p.i. (P = 0.003), respectively. Interest-
ingly, the tumor uptake of the trimeric compound lies in
between values reported for 64Cu-labeled dimeric and
tetrameric RGD bioconjugates with ~ 4 and ~ 10 %IA g−1,
respectively [11]. In comparison with the monomer, the
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trimer exhibited a higher tracer accumulation in all organs,
except for the stomach and the muscles. The increased organ
uptake may be explained by the higher number of RGD
targeting vectors with a higher binding affinity and avidity.
This is supported by the results of the blocking study, in
which the uptake in normal organs was significantly
reduced, confirming receptor mediated radiotracer accumu-
lation also in normal tissues. This is in accordance with the
literature, where αvß3 imaging probes demonstrated low but
blockable uptake in normal tissues [41–45]. However, the
blocking effect was less pronounced for the trimer than for
the monomer, which may be a result of the enhanced tumor
binding due to the three RGD targeting vectors and/or a
slightly higher fraction of non-specific binding. An amount
of 5 mg/kg c(RGDfK) was injected in the blocking group,
which has previously been used for confirming target
specificity but this amount may have been too low to
achieve a more pronounced blocking effect for the trimer
[32]. The highest radioactivity accumulation for [64Cu]Cu-9
was observed in the liver with 5.63 ± 1.61 %IA g−1 and the
kidneys with 7.65 ± 0.52 %IA g−1, suggesting excretion of
the tracer via the hepatobiliary and renal pathway. Kidney
and liver uptakes were blockable with 3.32 ± 0.09 %IA g−1
(P = 0.0084) and 5.45 ± 0.59 %IA g−1 (P = 0.1038), respec-
tively, indicating that accumulation in both organs was also
partially receptor mediated. Reported values for both organs
are comparable with the liver and kidney uptakes of a 64Cu-
labeled tetrameric c(RGDfK) bioconjugate [11]. The kidney
and liver uptakes for the monomer [64Cu]Cu-8 were 2.67 ±
0.33 %IA g−1 and 2.75 ± 0.05 %IA g−1, respectively,
comparable with those of other 64Cu-labeled RGD mono-
meric radiotracers [32, 46]. For both tracers, the tumor-to-
liver and tumor-to-kidney ratios of 0.84 and 0.86 for the
monomer and 0.99 and 0.73 for the trimer were moreover in
accordance with ratios of recently reported 64Cu-labeled
RGD monomeric analogs ranging from 0.70 to 1.13 [32,
46]. In that series, RGD radiotracers comprised different
metal chelators including NOTA-Bn-NCS and several TE2A
derivatives including cross-bridged TE2A [32, 46]. Despite
the relatively high molar mass of the trimer, the blood
uptake at 1 h p.i. was comparable or even lower than that of
other 64Cu-labeled radiotracers bearing only a single RGD
targeting vector such as DOTA-c(RGDfK), NODAGA-
c(RGDfK), and CB-TE2A-c(RGDfK) with 0.63 ±
0.14 %IA g−1, 0.31 ± 0.09 %IA g−1, and 0.49 ± 0.05 %IA g
−1, respectively [32].
In addition to the ex vivo biodistribution studies, the
pharmacokinetics of [64Cu]Cu-8 and [64Cu]Cu-9 were deter-
mined by small-animal PET imaging in mice bearing U-87MG
xenografts. As can be seen in Figs. 3 and 4, respectively, the
αvß3-positive U-87MG tumors as well as the liver and the
kidneys were clearly visualized by [64Cu]Cu-8 and [64Cu]Cu-9
on the PET images confirming the results of the biodistribution
study with the trimer [64Cu]Cu-9 exhibiting a ~ 2-fold higher
tumor uptake compared with its corresponding monomeric
part. As illustrated by corresponding time-activity curves
(TACs) in Fig. 5 obtained from dynamic PET imaging from
0 to 1 h p.i., tumor accumulation for [64Cu]Cu-8 and [64Cu]Cu-
9 was rapid with both compounds reaching maximum after ~
5–10-min post-administration followed by a decline until
20 min p.i. with no significant differences between the non-
blocking and blocking groups. After 20 min p.i., tumor uptake
for both radiotracers stabilized and persistent retention was
noted up to 24 h for both radiotracers with 2.80 ± 0.52 %IA cm
−3 for [64Cu]Cu-8 and 4.64 ± 0.91 %IA cm−3 for [64Cu]Cu-9 at
24 h, respectively. In the blocking group, the tumor uptake for
[64Cu]Cu-8 and [64Cu]Cu-9 was 0.74 ± 0.24 %IA cm−3 and
2.16 ± 0.64%IA cm−3 at 24 h p.i., respectively. Renal excretion
was rapid with kidney uptake peaking at ~ 5 min p.i. for both
compounds. After decreasing rapidly within the initial 20 min
p.i., kidney accumulation for both radiotracers plateaued to ~
3–5 %IA cm−3 at 1 h p.i. In contrast, a biphasic renal excretion
was observed for the monomer and the trimer in the blocking
group. Uptake in the liver was also rapid for both compounds
peaking at 5 min p.i. and rapidly decreasing to a plateau of ~ 4–
5 %IA cm−3 after 10 min p.i. No significant differences in liver
uptake between the normal and blocking groups were noted for
[64Cu]Cu-8 and [64Cu]Cu-9.
Altogether, both compounds exhibited favorable pharma-
cokinetics with rapid and persistent accumulation in the U-
87MG tumors together with rapid blood and kidney
clearance suggesting that both radiotracers may find appli-
cations in PET imaging of αvß3 integrin-positive tumors.
Noteworthy, in spite of the 2.5-fold higher molecular weight
of the trimer, the biodistribution profiles of both compounds
were comparable but with a ~ 2.5-fold higher tumor uptake
of the trimer, which may translate into higher sensitivity
compared with the monomer.
Conclusions
In this study, we developed the metal chelator NOTI-TVA 6
based on our chelating platform that allowed the covalent
conjugation of three targeting vectors via peptide bond
formation. A high yielding synthetic route for the NOTI-
TVA scaffold was established allowing synthesis on a
multigram scale. To investigate the feasibility of this
trifunctionalized chelator for radiopharmaceutical develop-
ment, biological evaluations in combination with three RGD
targeting vectors were performed. Results suggest that
aliphatic modifications at the non-coordinating NH groups
of the imidazole residues are well tolerated and that these
modifications had no measurable impact on the radiolabeling
properties of the NOTI-TVA 6 scaffold with copper-64. This
observation is in accordance with our previous findings on
the non-conjugated metal chelators NOTI and NOTI-Me.
Here, carboxylic acid groups were introduced for bioconju-
gation, but the system is highly flexible and can be readily
adapted to other types for bioconjugation such as copper-
free click chemistry. In line with reports on other multimeric
RGD-based radiotracers, in cell experiments in the αvß3-
positive U-87MG cell line, the trimer displayed a higher
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binding affinity and internalization than its monomeric
counterpart. The 64Cu-labeled trimer also displayed superior
tumor uptake in ex vivo biodistribution and PET imaging
studies with a ~ 2.5-fold higher tumor accumulation con-
firming the concept of increased local concentration at the
target site by multimerization. Altogether, we showed that
multiple functional groups for bioconjugation as well as
additional peptidic targeting vectors can be introduced to
NOTI 1 without compromising its metal binding properties.
The straightforward modification of the imidazole arms of
NOTI 1 by nucleophilic substitution paves the way for
multiple applications of our chelating platform in radiophar-
maceutical development. In combination with the recently
described protection/deprotection strategy for the TACN
macrocycle, not only compounds with up to three identical
targeting vectors based on NOTI 1 are now at hand but,
more importantly, also radiotracers comprising various
different substituents such as different targeting vectors
and/or fluorescent dyes are accessible by this approach.
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